Duopharma Biotech Bhd 2023 Integrated Report
Company: Duopharma Biotech Bhd
Sector: Manufacturing
Country: Malaysia
Year: 2023
Type: Integrated Report
Pages: 264
The report describes a year of continued growth, with consolidated 2023 revenue of RM704.73 million despite higher operating costs. It highlights the Board-approved Net-Zero Transition Plan supporting carbon neutrality by 2030 and net-zero carbon emissions by 2050, alongside solar installations, Scope 3 assessment and resource-efficiency initiatives. The report also presents 2023 ESG performance data, including 39,619.59 tCO2e of carbon emissions generated, 201,188.50 Gigajoules of energy consumption and 1,544.59 metric tonnes of waste generated. Limited independent assurance was obtained from Carbon Check (I) Pvt. Ltd. using AA1000AS v3.
Reporting standards, commitments and assurance details are available with a free account.
Data Services
From bulk PDFs to structured indicators and machine-readable documents.